Sustained impact of subcutaneous immunotherapy among patients with allergic rhinitis who experienced treatment delay due to the COVID-19 pandemic: A multicenter, two-arm, real-world study

Clin Transl Allergy. 2022 Mar 1;12(3):e12122. doi: 10.1002/clt2.12122. eCollection 2022 Feb.

Suizi Zhou^{1

2

3}, Yibin Liu^{1

2

3}, Jianrong Xue⁴, Jun Tang⁵, Qingqing Yu⁵, Shenhong Qu⁶, Shaojie Zhang⁶, Binyu Mo⁷, Jihui Li⁷, Yinhong Liu², Yueying Yang^{1

2

3}, De-Yun Wang⁸, Qianhui Qiu^{1

3}

¹ Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
² Department of Otolaryngology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
³ The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
⁴ Department of Otorhinolaryngology, The Third People's Hospital of Changzhou, Changzhou, China.
⁵ Department of Otorhinolaryngology, The First People's Hospital of Foshan, Foshan, China.
⁶ Department of Otorhinolaryngology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
⁷ Department of Otorhinolaryngology, Liuzhou People's Hospital, Liuzhou, China.
⁸ Department of Otolaryngology, National University of Singapore, National University Health System, Singapore, Singapore.

No abstract available

Keywords: COVID‐19; delayed therapy; depression; efficacy; subcutaneous immunotherapy (SCIT).